This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

No abstract

Ozurdex (Allergan Inc., Irvine, CA, USA) is a biodegradable implant of dexamethasone (0.7 mg) injected into the vitreous cavity to treat macular oedema. We report a case of migration of Ozurdex into the anterior chamber in a patient who had a previous iris-claw lens implantation. Surgical removal of the implant was avoided due to the absence of anterior complications and the loss of effectiveness of the drug delivery system. Repositioning of the implant to the posterior segment is described. This case illustrates the efficacy of this technique in cases of migration into the anterior chamber in eyes without corneal decompensation.